Table 3.

Glomerulosclerosis at 15 Weeks of Treatment

Group	No. per group	Glomerular area (pixels)	PAS-positive area (pixels)	PAS-positive/total area (%)
3-mg/kg dose
C57BL/6 + saline	6	72,514 ± 6595	16,470 ± 4231	22.6 ± 4.4
C57BL/6 + LSKL	6	77,791 ± 7613	17,888 ± 4726	23.1 ± 6.1
C57BL/6 + SLLK	6	67,672 ± 11,591⁎	15,242 ± 3851	22.7 ± 5.1
Akita + saline	17	87,924 ± 18,704	24,196 ± 5485†	27.4 ± 4.7
Akita + LSKL	19	94,705 ± 12,122	28,530 ± 5190‡	30.4 ± 5.5§
Akita + SLLK	18	93,465 ± 10,982	25,441 ± 4725§	27.3 ± 4.6
30-mg/kg dose
Akita + saline	9	85,748 ± 8605	23,998 ± 5787†	28.4 ± 7.7
Akita + LSKL	9	93,209 ± 12,965	24,229 ± 3556†	26.1 ± 2.8
Akita + SLLK	9	88,503 ± 7450	22,607 ± 3157†	25.4 ± 2.0

Data are given as mean ± SD. Analysis of variance with Student-Newman-Keuls post hoc analysis.

^⁎P < 0.05 versus low-dose Akita saline, LSKL, SLLK; and high-dose saline, LSKL, SLLK.

^†P < 0.05 versus C57BL/6 saline and SLLK.

^‡P < 0.05 versus all C57BL/6 groups and high-dose SLLK.

^§P < 0.05 versus all C57BL/6 groups.